ESG

The beef giant's record R$57 billion annual revenue signals resilience, even as missed earnings and trade headwinds present complex challenges ahead.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

The environmental services firm posted sequential growth and cut costs, signaling a strategic pivot despite a year-over-year revenue dip.

Aptar Pharma and the FDA lead a critical mission to reinvent respiratory medicine, ensuring patient safety while tackling the climate impact of inhalers.

The chipmaker topped Q1 estimates and eyes a strong Q2, fueled by EV and AI markets, even as restructuring charges weigh on its bottom line.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

With its stock at an all-time high, Ross Stores' upcoming earnings will be a critical test for the off-price sector's resilience and consumer spending.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

With a May 22 deadline, conservation groups are racing to apply for a share of $160 million dedicated to protecting Minnesota's natural legacy.

A merger of two innovation hubs, backed by industry giants, forms the Novara Energy Alliance to tackle the region's pressing energy and water crises.

A new AI-powered technology can spot deadly high potassium levels using a simple smartwatch ECG, a breakthrough that could transform remote patient care.

Dr. David Rankey joins Wellvana as CMO, a strategic move as the company scales its model and the industry shifts from proof of concept to performance.

With its new CCO, the AI health-tech firm aims to commercialize its patient-data platform, tackling billion-dollar delays in drug development.

With new SAFE financing, Cubit Diagnostics advances its all-in-one molecular and immunoassay platform, aiming to revolutionize point-of-care STI testing.

The Italian pharma giant appoints a global health policy heavyweight, signaling a strategic pivot towards tackling complex global challenges and a new era.

With key leadership hires, Hudson Valley Property Group is scaling up to meet soaring investor demand for impact-driven affordable housing preservation.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A massive $250M investment could replace a 40-pill daily burden with a single tablet for patients with pancreatic insufficiency, disrupting a market in crisis.

A new survey finds most mothers reject the 'routine' label, feeling strong in daily acts. One FemTech firm is now championing a shift from sacrifice to celebration.

From the makers of the 'World's Best Tequila,' a new Reposado redefines aging with a unique blend of Sauternes, Sherry, and Bourbon casks.